Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hey, hey, all New York jerks are not typical.
This all sounds good to me. Let's see how it plays out.
Actually, you should just look at the form. They exercised old warrants from 2021 and 2019.
So, if the machine comes tomorrow, or next week, or the one after that is that no honesty? Or is in an inability to foretell the future worth certainly.
My point was that you want the company to tell you when something will happen before it happens, Not that they tell you in advance. If you get a prediction there is always a degree of uncertainty. That's the way it is. You make money in the markets by buying uncertainly, (risk), not by buying certainty.
you want information in advance and you want accurate information. Do you see the issue?
What gets old is your non-stop attacks on the company and your impatience. It's a risk reward play, either it happens or it doesn't. If it happens you get rich if not you lose what you put in.
The delivery is in the hands of Kommarck, not the biof. there are delays all over the place.
You seem to be confused about who "the company" is, or at least write as if you are. The company is not PRED, it is HLTT. PRED has not been putting out news, although I understand their reluctance given their history with the SEC and news releases. HLTT is putting out news on a regular schedule. From HLTT's news releases, we can glean at least part of what is going on with PRED. I think we'll be fine.
HLTT came out with a letter to stock holders in which it said that it sold 776k of it's wound care products in September and an increasing amount every month since in the fourth quarter. The letter is below and also filed with the SEC.
HEALTHTECH SOLUTIONS, INC.
181 Dante Avenue
Tuckahoe, New York 10707
Annual letter to our shareholders and employees
Greetings:
As the new year emerges, I am using this occasion to reflect on the progress made by your company (“HLTT”) during 2022 and the prospects that we see for 2023. We ended 2021 as a medical technology incubator with only a series of scanning technologies, all of which were a distance from potential revenue. We ended 2022 with multiple profit centers already generating substantial revenue or poised to do so.
Our growth during 2022 can be understood as expansion in three integrated vectors: expansion of technology, expansion of skills, expansion of markets. I will summarize our principal accomplishments in each.
Technology: Acquisition of Wound Care IP.
In January 2022, HLTT acquired the assets of a Utah-based biomedical company related to production of wound care treatments. These assets included an FDA licensed manufacturing facility with equipment, intellectual property, including patents, related to wound care, and a skilled management team. The team included the Laboratory Director, the Chief Laboratory Officer, the Senior Vice President of Quality and Regulatory, and the Chief Medical Officer of the manufacturing lab facility.
In the Spring of 2022, we completed the licensing of our initial wound care product line and appointed World Reach Health, LLC (“WRH”), an experienced distributor of biomedical products (more on WRH below), to develop a market for our wound care products. That market produced its first sales in September 2022, and we reported net revenue of $776,221 for that month. We have recorded increased wound care revenue for each month in the fourth quarter of 2022, and we expect wound care revenue to continue to grow during 2023.
Skills: Acquisition of World Reach Health.
Our relationship with World Reach Health grew throughout 2022, as we saw the potential for mutual benefit to HLTT and to WRH from an enhanced relationship. Jelena Olmstead and Jim Pesoli, the owners and principals of WRH, each worked closely with HLTT management to build the HLTT wound care business. They were also instrumental in establishing our new CLIA lab (see below).
In December 2022, the growth of the relationship culminated in the execution of a binding contract under which HLTT will acquire 51% of the membership interest in World Reach Holdings, the parent company of World Reach Health (WRH). The closing will occur in January 2023. WRH is a distributor of biomedical products and medical devices. It sells directly to medical professionals and also has established a nationwide network of sub-distributors.
1
The acquisition will provide HLTT assurance of access to markets for the products and services that its subsidiaries develop. Of equal significance, the acquisition will bring into HLTT management the skills and experience provided by Jelena Olmstead and Jim Pesoli. At the closing of the World Reach Holdings transaction, Jelena will become the CEO and Jim the Senior Vice President of HLTT.
Jelena Olmstead. With over 20 years of experience in distribution of medical products and services, Jelena has familiarity with all continuums of care: Acute, LTC, Home Health, Hospice and Wound Care Clinics. Jelena was intimately involved in developing of annual sales strategies and plans, developing Wound Care processes, establishing best practices, and launching many emerging products into the market, while managing national sales and operations teams. Prior to organizing World Reach Health, Jelena served as Director of Business Development for NuMotion, which specialized in medical devices for mobility needs. Jelena was personally involved in the distribution of more than $1.5 billion worth of goods annually over the course of her career. Prior to joining NuMotion, Jelena was the Business Development Director and Key Account Manager for Invacare and for Joerns, both global healthcare manufacturers and distributors of DME and medical devices. Jelena was involved in a multitude of M&As throughout her career.
Jim Pesoli. Jim’s 15 years of experience as a healthcare-services executive and transactional attorney commenced when he began negotiating international manufacturing and distribution agreements for a variety of commodities and/or intellectual property rights. Later, he founded and eventually sold, Sonic Cleaning Services, which provided housekeeping and laundry services to nursing homes, assisted living facilities and healthcare institutions throughout the Midwest. Throughout his career, Jim has maintained close relationships with the distributors and manufacturers he represented or worked with. Additionally, as an entrepreneur, Jim has raised over $100 million in venture capital for a myriad of enterprises. Within World Reach Health, Jim has been instrumental in identifying and establishing strategic partnerships and brokering long-term purchasing agreements with product suppliers and purchasers around the globe.
WRH has ongoing contracts to distribute a number of products. These include Endurakit, a non-opiate surgical block for which WRH is one of four national distributors. WRH is the exclusive distributor for MY GEL, which is a neuropathy pain gel. WRH is also an approved distributor for some of the leading COVID-19 diagnostic tests, along with other diagnostic products, which are manufactured by AccessBio and Phase Scientific. WRH is a distributor of the Postday One-Step emergency contraceptive, and WRH is also an authorized distributor of Better Air, which provides organic probiotic air purification solutions. In this fashion, we expect WRH to provide a gateway to market for the products developed by HLTT subsidiaries as well as a source of additions to HLTT’s product list.
2
Markets: Organization of The Clia Lab.
Our current business plan points towards integration of complementary product and service lines, with the goal of maximizing the potential market for products and services developed by our subsidiaries. For example, WRH is well-established as a distributor in the rapid-testing market, which includes testing for Flu, Covid and Mersa. To optimize the opportunities presented by WRH’s presence in that market, the logical next step was to organize our own lab.
In the second half of 2022, therefore, we established an FDA-licensed CLIA laboratory, appropriately named “The CLIA Lab.” This facility is housed at the University of Utah technology campus in Salt Lake City.
The CLIA Lab is licensed to perform the Flu, Covid and Mersa tests that WRH has to date sold for other labs. It is also licensed to perform bacteria testing, providing a new revenue stream for WRH as well as a market advantage for HLTT’s wound care products. We expect to offer bundle packages to our wound care providers, which will include both the clinical test required prior to a wound care treatment as well as the wound care allograft that HLTT manufactures.
The View Forward
The acquisition of WRH later this month will provide HLTT a soup-to-nuts integration of the facilities required to develop biotechnical products and bring them to market. The only external input necessary for significant growth will be funding. Towards that end, management is in discussions with several broker-dealers with a view toward one or more of them sponsoring the uplist of HLTT’s shares to the NYSE American or NASDAQ. We plan to initiate the uplist process, soon after we file our 10-K Annual Report for 2022.
In sum, management expects 2023 to be HLTT‘s breakout year. We thank you for the support and dedication you have shown the company since 2020. We pledge to work tirelessly to assure that your confidence will be well rewarded.
Sincerely,
Manuel E Iglesias, President
Healthtech Solutions, Inc.
January 6, 2023
We're not above dragooning.
Welcome aboard.
I think it's 150 million tons a year. forty percent of the total crop of 384 million tons.
https://www.statista.com/statistics/686193/production-of-corn-us/
https://civileats.com/2022/02/14/how-corn-ethanol-for-biofuel-fueled-climate-change/
Or from the University of Illinois.
https://farmdocdaily.illinois.edu/2020/03/corn-used-for-ethanol-update.html
5.4 billion bushels per year, 56 pounds in a bushel.
50k tons or 50 tons??
Just curious, as you and I seem to be the only ones here, who are you? I'm an investor in pred who is following HLTT because while PRED gives no info at this time, HLTT seems to give some info on PRED.
Clearly someone is selling, but
We don't know if it is a short, a year end tax loss seller, someone who got some margin calls, or something else. But you may notice is that there is some buying as well. We don't know what is going on, or at least I don't, but we do know that it is year end and the new machine is coming next week.
There will be news about the testing of that machine. They already tested it at the Komarek plant earlier in it's stripped down configuration as I understand it, so there should be no surprises. As I said before, short term price moves don't matter now.
I just wish I had some more money.
Day to day price variation is irrelevant. If they can make this work, we will all do very, very well. If not, well then not.
The markets don't correctly evaluate these stocks on a day to day basis like AAPL or AMZN. If you weren't planning to sell in the next week, then who cares.
Thanks.
It's behind a paywall. Can you tell us what it says?
Thanks for the post.
I do believe they have the technology and it works. The only thing now, is can they bring it home. I'll wait.
HLTT, pred's partner in wound care, posted its 10Q last month. 776k sales of pred's allograft in September. Looks good.
"Sales of our wound care allografts commenced in September 2022, as we delivered allografts to five customers for an aggregate purchase price, net of discounts, of $776,221. Payments for the sales did not commence until October, so we recorded accounts receivable from the sales of $720,777, representing the net sales revenue less an allowance for doubtful accounts of $55,444. After recording $51,834 in cost of goods sold (i.e. proportionate allocation to the products sold of the direct costs attributable to their production), we recorded gross profit of $720,175 for the three and nine months ended September 30, 2022. We expect that in future periods our gross margin ratio will be lower than the ratio we recorded in the periods ended September 30, 2022."
https://www.otcmarkets.com/filing/html?id=16221949&guid=xrG-kWHM7TC6dth
Where do you see quotes?
I know on Think or swim they have the last quotes up from before they went dark, and they never change.
Are you asking because there has been some consistent trading, if low price and volume? I didn't think there was a 211, but I tried to place a buy order just in case. No luck. There must be some way to buy this stock because people are, but not through any broker I have.
If you look at these as pure risk reward plays, and factor in the risk of untrustworthy principals, then it's all part of it. You made a bet and you just wait for the end.
You said you only have warrants. That means you must have had stock and sold it. Did you make a profit on that stock? If so, you are now in a position with locked in profit and a free lottery ticket. Why are you complaining. Put another way, if a profit and free warrants doesn't make you happy, what would make you happy.
Even if you didn't sell for a profit, you're still doing well. You paid a little for your lottery ticket. Don't worry, be happy.
I think you buried the lede, NDA. The real news is the patent was granted on November 1. That means they have two patents and if you look the first one is essentially the same as the first and was assigned to Allm.
Very good news.
https://patents.justia.com/inventor/benjamin-slager
This is probably what it is. Hit everyone alternative energy.
https://www.reuters.com/business/energy/energy-market-turmoil-shakes-europes-green-power-plan-2022-11-03/
otoh, if they were doing something nefarious, why call it Predictive? Besides, there is no way they could get away with stealing from the stockholders, especially since there are big guys, like Merle, involved.
I doubt that, but it is interesting. The word biologics means any treatment derived from living things, like stem cells or bacteria. Remember that PRED transferred to HLTT the previous division that did stem cells. Maybe they have a new stem cell or other biologic product and they need a vehicle.
It's not listed as a subsidiary, so that is strange.
I think you're right about PRED. I've got some of that too.
Don't worry Bigboy36, everybody learns that lesson the same way. I know I did.
and PIW, you disappeared, what happened?
Moderately heavily in ELGL, none in BFNH. A portion of my money goes into high risk high reward stocks. So, I'm safe as far as a full disaster is concerned. If they all go to zero I'm okay.
I look at these as risk reward plays, like a poker bet. I don't play poker but I understand the principals. Then I apply a kind of Bayesian analysis to it. (How likely is this fact to be true if the stock is going to go down, how likely is it if the stock is going to go up.) The fact that the big guys are still there, LaVoilette, etc., makes it more likely that this will succeed.
So if you figure there is a 50% chance of success and a ten bagger or more if it succeeds, then it's a no brainer. One final thing, it's a good idea to have a few of these. If you have three noncorrelated 50% bets, your chance of all of them going down the tubes is about 12.5%. So, again, pretty good risk reward.
That's my take anyway.
Well. One verification. All the heavy hitters are still there.
Nothing of note. Just more waiting
Piw wrote: My guess is none of us truly understand how large this could be.
Oh, you have no idea how big my fantasies can be.
I just wish they'd put something out to let us know what is going on, at least a little bit. But I guess they can't.
I doubt if anyone will need tax loss selling this year. The company should get the next version by the end of the year so we'll see what that brings.
I think the site is very good, gives the story of the company to new potential investors very well. I like the analogy of plants, and the cellulose inside them, being nature's battery. It calls attention to the weakness, or incompleteness, of wind and solar as energy sources.